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Rationale: COPD is a debilitating disease with increasing mortality worldwide. The BODE index
evaluates disease severity and the St George’s Respiratory Questionnaire (SGRQ) measures
health status.
Objective: To identify the relationship between BODE index and the SGRQ and to test the
predictive value of both tools against survival.
Methods: Open cohort study of 1398 COPD patients (85% male) followed for up to 10 years.
Measurements and main results: At the time of the inclusion, clinical data, forced spirometry
and 6 min walking distance were determined and BODE index and SGRQ were calculated. Vital
status and cause of death were documented at the end of follow-up.
Results: The cohort’s mean of FEV1% predicted was 46  18%, BODE index was 3.6  2.5, and
SGRQ% total score was 49  20. The SGRQ scores increased progressively as severity of COPD
increased by BODE quartiles. The correlation between SGRQ and BODE index was good
(r Z 0.58, p < 0.0001). Both tests correlated with COPD survival (BODE Z 0.4 vs.
SGRQ Z 0.20, p < 0.0001). The area under the curve (AUC) for the BODE index was 0.77
vs. 0.66 for the SGRQ % total score (p < 0.001).Service, Hospital Miguel Servet, Avda Isabel la Cato´lica 1-3, Zaragoza 50006, Spain. Tel.: þ34 976
s (J.M. Marin).
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the BODE index. Both tools predict mortality and provide complimentary information in the
evaluation of patients with COPD.
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Chronic obstructive pulmonary disease (COPD) is a progres-
sive chronic respiratory illness, which is rapidly becoming
a leading cause of mortality and disability worldwide.1 The
disease is associated with both respiratory as well as multi-
systemic impairment that often impacts on the functional
capacity of patients, and in their ability to perform normal
activities of daily living affecting their quality of life.2
Health Related Quality of Life (HRQoL) is an important
patient reported health outcome that is currently receiving
increasing recognition.3 The impairment in HRQoL in COPD is
seen even at levels of relatively modest airflow limitation.4
This weak association between HRQoL and the forced expi-
ratory volume in 1 s (FEV1) has long been described and
reflects the marked heterogeneity and complexity of this
disease.5 The dissociation between FEV1 and patient
centered outcomes such as HRQoL, and even survival has
prompted an increasing interest in the multi-systemic eval-
uation of COPD. The BODE index is a multidimensional
instrument that incorporates measurements of nutritional
status, the Body Mass Index (BMI), airflow limitation (FEV1),
dyspnea, Modified Medical Research Council (MMRC) and
functional status as measured by the 6-min walk distance
test (6MWD).6 BODE provides an integrated evaluation of the
respiratory and non respiratory expressions of the disease
that better reflects disease severity. BODE also includes
domains that relate to the quality of life of patients with
COPD. BODE has been shown to predict mortality,6e8
hospitalizations9 and to be sensitive to change with inter-
ventions like pulmonary rehabilitation10 and surgical
procedures like lung volume reduction surgery (LVRS).7,8 The
same interventions have also been associated with mean-
ingful improvements in HRQoL.10e13 Conversely, it is well
known that exacerbations cause worsening of HRQoL.14 We
have recently shown that exacerbations significantly
contribute to worsening disease severity of COPD as
measured by the BODE Index.15 So, it is quite possible that
changes in the BODE indexwould translate in better or worse
HRQoL for patients with COPD. The St. George’s Respiratory
Questionnaire (SGRQ) is a disease specific quality of life
instrument designed to assess the quality of life of patients
with COPD.16 The SGRQ score has also been shown to have an
association with increased health care resource utilization
(HCRU)17 and with decreased survival.18 SGRQ is also
responsive to pharmacological and non-pharmacological
interventions.11,12,19 Some studies suggest a relationship
between BODE index and SGRQ but the studies have included
a limited number of patients with short follow up and none
has explored the relative value of either test to predict
survival.20,21
The primary purpose of this study was to explore the
possible correlation between disease severity as measuredby the BODE index, and HRQoL as measured by the SGRQ in
a large cohort of patients with COPD. In addition, we aimed
to determine thresholds of critical value for both the BODE
index and the SGRQ in relation to COPD mortality, and to
compare the two instruments in their capacity to predict
survival in this disease.
Methods
Patients
A total of 1398 patients with COPD as accepted by the
American Thoracic Society (ATS)2 were sequentially recruited
into an observational study, between January 1997 and
September 2006, at several of the BODE study sites. Inclu-
sion/exclusion criteria have been previously published.6 The
protocol was approved by the institutional review board of
each institution and all patients signed a consent form.
Measurements
Baseline data were collected in clinical stable conditions
that are at least one month after COPD exacerbation.
Pulmonary function test was obtained according to the
ATS.22 The 6MWD was performed following ATS guidelines.23
Dyspnea was assessed using the Modified Medical Research
Council Dyspnea Scale or MMRC scale.24 The BODE index
was measured and staged in quartiles as previously pub-
lished.6 To determine HRQoL we used the validated SGRQ
questionnaire.16 For the purpose of this study, the SGRQ %
total scores were divided into quartiles as follows: Q1 <25,
Q2Z 25e49, Q3Z 0.50e74 and Q4  75. Co-morbidity was
measured by the Charlson score.25
Follow-up and outcome
The patients were followed at six month-intervals until
August of 2007 or until death. Data for mortality was
confirmed by reviewing the medical records and by con-
tacting patient’s next of kin in every site.
Statistical analysis
Normally distributed variables are reported as me-
an  standard deviation (SD). ANOVA was used to compare
baseline characteristics for intra and inter-group. Pearson’s
correlation coefficients were obtained between different
variables and SGRQ. Kaplan Meier survival analysis was use to
assess survival byBODE and SGRQquartiles. Logistic regression
analysis using survival and COPD survival as dependent vari-
ables was used to assess the contribution of variables showing
significant correlations with these outcomes. We computed
918 J.M. Marin et al.the C-statistics to compare the power of the BODE and SGRQ
values to predict mortality. In this analysis the area under the
receiver operating curves (ROC) were quantified and
compared to assess the performance of both indices. All
analyses were run with STATA version 11.1
Results
Baseline characteristics
A total of 1398 patients with COPD were included in the
study. The patients were followed for 53  28 months or
until death. Most patients had symptomatic COPD. 7% of
patients were in stage I by GOLD classification, 31% in stage
II, 41% in stage III, and 21% in stage IV. The mean SGRQ %
total score was 49.6  20. The baseline characteristics of
patients divided according to disease severity by BODE
quartiles are shown in Table 1.
Relationship between BODE and SGRQ
The relationship between the components of the SGRQ and
the BODE index are shown in Table 2. The SGRQ total
correlated better with BODE index than with FEV1%
(r Z 0.58, vs r Z 0.37, both p < 0.0001). The activity
domain of the SGRQ correlated best with all of the
components of BODE No SGRQ domains correlated with BMI.
Overall, we found that the SGRQ scores worsened expo-
nentially as disease severity increased by BODE quartiles.
When the analysis was done separately for each country,
the SGRQ-BODE relationships were similar; therefore, the
data are presented together. The activity domain and the
impact domain scores of the SGRQ, showed the most
increase from quartile 1 to 4 (47.7% and 43% respectively),
while symptom scores increased only 30%.On the other
hand, the difference in SGRQ total score of patients from
quartile 1 to 4 exceeded 50%.Table 1 Baseline characteristics of patients according to disea
VARIABLES ALL, n Z 1398 Q1, n Z 483
Follow-up (months) 53  28 53  31
Age (years) 66  9 65  9
Gender (male %) 85 83.8
Post BD FEV1 (L) 1.35  0.58 1.89  0.58
Post BD FEV1 (%) 46  18 62.5  16
MMRC (Points) 2.12  1.1 1.15  0.7
6MWD (Meters) 387  130 475  80
BMI (Kg/m2) 26.8  5.5 28  5
BODE Index (Points) 3.63  2.5 1.2  0.8
Charlson (Points) 4.16  2.4 3.45  2.3
SGRQ Symptoms 54.2  24 43.4  24
SGRQ Impact 39.4  22 27  20
SGRQ Activity 65.3  24.6 48  23
SGRQ Total 49  20.4 36  18
ANOVA: **Intra and inter-group comparison, p< 0.05, * Only Q4 is diffe
BODE: Body mass index, Obstruction, Dyspnea, Exercise capacity; Po
bronchodilator; MMRC: Modified Medical Research Council Dyspnea ScMortality
There were 430 deaths during the study period (30.8%). The
mean follow-up time from enrollment to death was 38  24
months. Most deaths (nZ 296, 68.8%)were due to respiratory
causes: 49.5% were directly related to COPD, 15.8% to lung
cancer, 2.6% to lower respiratory tract infection and 0.7% to
pulmonary embolism. Cardiovascular diseaseswere the cause
of 8.8% of deaths and 8.1% died to malignancies other than
lung cancer, 4.7% to various medical or surgical illnesses and
in 9.8% the cause of death could not be determined.We found
both tests (the BODE index and SGRQ total) to correlate with
all causemortality (rZ 0.34, p< 0.001 and rZ 0.19, p< 0.01
respectively). BODE correlation with COPD mortality was
r Z 0.41, p < 0.0001, while SGRQ correlation with this
outcome was: rZ 0.21, p < 0.001. The correlations of BODE
and SGRQ with non-COPD death were non-significant: 0.06
and 0.03 respectively.
When the cohort was stratified by BODE quartiles or by
SGRQ quartiles, as expected median survival decreased as
quartiles increased for both indexes but there were no
differences in the median survival among BODE vs SGRQ
quartiles (Table 3). We also used Kaplan Meier analysis and
compared the survival of patients divided by SGRQ quartiles
and by BODE quartiles (Fig. 1). Mortality of patients with
SGRQ Q4 was 64% vs BODE Q4 which was 63%. Overall, SGRQ
and BODE quartiles survival curves were different, but
these differences appear better defined when the cohort
was grouped in BODE quartiles. Logistic regression analysis
with all cause mortality as dependent variables showed:
age, BODE, and Charlson index as the only elements of the
model (unadjusted r2 Z 0.34, p < 0.001). Changing the
BODE index with the SGRQ total, the model included age,
Charlson index, FEV1%, 6MWD and BMI as independent
variables predicting total mortality (unadjusted r2 Z 0.33,
p < 0.001) (Table 4). The C-statistics was 0.77 for BODE
index and 0.66 for SGRQ total score, with a difference in of
0.11 (95% confidence interval, 0.08e0.05, p < 0.01),se severity by BODE quartiles.
Q2, n Z 457 Q3, n Z 270 Q4, n Z 188
55  28 53  29 52  31
66  9 67  9 67  9
84.6 83.7 94.6*
1.32  0.5 1.07  0.4 0.86  0.3*
42.9  12.5 36  13 28  10**
2.08  0.7 2.94  0.6 3.64  0.5**
414  91 319  95 179  90**
27.2  5.6 27  6 25  6*
3.5  0.5 5.4  0.5 7.9  0.9**
4.16  2.4 4.44  2.3 5.22  2.4**
56  24 63  23 70  20**
37  19 46  20 57  18**
64  21 77  18 87  14**
48  18 58  17 68  13**
rent from others. SGRQ: Saint George’s Respiratory Questionnaire;
st BD FEV1: Forced Expiratory Volume in 1 s 20 min after inhaled
ale; 6MWD: Six-Minute Walking Distance; BMI: Body Mass Index.
Table 2 Pearson’s correlations coefficients (with p values) for SGRQ % total and the components of the BODE index.
Domains BODE FEV1% MMRC 6MWD BMI
SGRQ % Symptoms 0.4 (p < 0.001) 0.28 (p Z 0.002) 0.41 (p < 0.001) 0.34 (p < 0.001) 0.02 (p Z 0.18)
SGRQ % Activity 0.59 (p < 0.001) 0.39 (p < 0.001) 0.63 (p < 0.001) 0.52 (p < 0.001) 0.02 (p Z 0.18)
SGRQ % Impact 0.5 (p < 0.001) 0.32 (p Z 0.003) 0.53 (p < 0.001) 0.43 (p < 0.001) 0.03 (p Z 0.08)
SGRQ % Total 0.58 (p < 0.001) 0.37 (p < 0.001) 0.61 (p < 0.001) 0.5 (p < 0.001) 0.02 (p Z 0.18)
SGRQ: Saint George’s Respiratory Questionnaire; BODE: Body mass index, Obstruction, Dyspea, Exercise capacity; FEV1: Post-bron-
chodilator Forced Expiratory Volume in 1 s 20 min after inhaled bronchodilator; MMRC: Modified Medical Research Council Dyspnea Scale;
6MWD: Six-Minute Walking Distance; BMI: Body Mass Index.
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all cause mortality (Fig. 2).
Discussion
To our knowledge this is the largest study of quality of life
performed in a cohort of patients with well characterized
COPD, followed over an extended period of time and not
partaking on a pharmaceutical clinical trial. Our study has
several novel findings. First, it shows that there is a better
correlation between the BODE index and the SGRQ quality
of life questionnaire, when compared to the gold standard
FEV1. Second, we have found that the SGRQ scores worsen
as COPD severity increases by BODE index quartiles
(Table 1). Third, the BODE index is more strongly associated
with mortality in COPD than the SGRQ scores. Finally, we
have confirmed prior observations about the impact of co-
morbidity in the HRQoL of patients with COPD,4 using the
validated Charlson score.25
Over the last few years it has become evident that
patients with COPD may express important multi-systemic
involvement, as evidenced by malnutrition, muscle
wasting, anemia, osteoporosis and depression. In patients
with clinical disease and a wide range of airflow obstruc-
tion, it has been shown that several of these factors are
better predictors of survival than the simple degree of
airflow limitation as measured by the FEV1.
18,26e28 That’s
why recent reviews propose that the global assessment of
an affected patient should include different aspects of the
consequences of this disorder, beyond the “gold-standard”
assessment of airflow limitation.29
The BODE index was a better predictor of outcome than
the FEV1 in a large cohort of patients with COPD,
6 and
better than all of the individual components of the index in
patients undergoing lung volume reduction surgery.7
In parallel with these observations, it has become evident
that the clinical complexity of COPD can not solely beTable 3 Median and 95% Confidence Interval (95%CI)
survival by BODE quartiles and Total SGRQ quartiles.
SGRQ
Quartiles
Months
(95%CI)
BODE
Quartiles
Months
(95%CI)
Q1 (<25) 60 (55e64) Q1 (0e2) 62 (57e66)
Q2 (25e49) 56 (50e62) Q2 (3, 4) 56 (51e61)
Q3 (50e74) 52 (47e60) Q3 (5, 6) 52 (48e59)
Q4 (75) 50 (44e56) Q4 (7e10) 49 (44e50)
P value for trend <0.001 <0.001expressed in physiological terms but that the actual
compromise of a patient may also be expressed by tools that
reflect the quality of their life. The disease specific
St. George’s Respiratory Questionnaire is perhaps the most
widely used and better tested of those instruments available
for patients with COPD. It has proven to be responsive to
several interventions in COPD such as pharmacological
agents,19,30 pulmonary rehabilitation12,13 and lung volume
reduction.11 Secondary analyses of some of those studies
have also suggested that the SGRQ can be useful in predicting
survival, although one study using a different disease specific
questionnaire, the CRQ, failed to observe an association
between the scores obtained and mortality.31 Our results
indicate that both instruments (the BODE index and the
SGRQ) in a way reflect the severity of COPD as conventionally
graded with the FEV1 and show that the correlations of SGRQ
and BODE were stronger than with airflow obstruction.
The BODE index and SGRQ have a significant but modest
correlation between themselves indicating that they do not
measure the exact same dimension (Table 2). Interestingly,
the best correlations between BODE and SGRQ domains were
seenwith activity and impact and not with symptoms, in spite
of the fact that there is a very good correlation between
MMRC and SGRQ, indicating that functional capacity is likely
a veryimportant determinant of quality of life in COPD.
Both, the BODE index and the SGRQ scores are moderate
predictors of survival. However, using all cause mortality as
the outcome, the BODE index proved to be superior to
the simultaneously obtained SGRQ (Fig. 2). The most
likely explanation for this finding reflects the development
and reasons for instrument development; whereas the
St. George’s questionnaire was developed to evaluate and
reflect patient’s physical, emotional and social well-
being,16 the BODE index was specifically designed and
validated to predict mortality in patients with COPD.6
Indeed, all four components of the index have been found
to be independent predictors of outcome and in aggregate
well express the multidimensional severity of an individual
patient’s disease state. On the other hand, the perceptive
compromise of well-being may be better reflected by the
SGRQ than by the BODE as that questionnaire was specifi-
cally developed for that purpose.
This study was not meant to prove that one instrument is
better than the other. Rather it was designed to evaluate
similarities and differences. We believe the results show
that one should not be used as a reflection of the other. We
view the evaluation of health related quality of life as an
outcome in of itself, of important value like health resource
utilization or even mortality can be. Indeed, quality of life
Figure 1 Kaplan Meier survival analysis using SGRQ total
quartiles and BODE quartiles. Although Chi square for trend are
significant among BODE and SGRQ total quartiles, individual
BODE quartiles differed each other while Q2 and Q3 of the
SGRQ total, had the same cumulative survival.
Figure 2 ROC curves revealed that an SGRQ total score of
55% and a BODE index score of 4 had the best sensitivity and
specificity to predict survival in COPD. The area under the
curve was significantly greater for BODE than for SGRQ.
920 J.M. Marin et al.has become and should continue to be one of the outcomes
evaluated when planning interventions as it better
expresses the composite effect of the intervention on
patient’s well-being. On the other hand, the BODE index
better reflects stages of COPD if mortality is considered the
ultimate expression of disease severity. Further, BODE has
proven sensitive to reflect exacerbation severity,15 the
response to surgery7,8 and to pulmonary rehabilitation10
and as such, is beginning to emerge as a tool to assess
disease modification and future disease outcome. Perhaps,
new studies underway, can use the strength of both tools to
express the complex nature of COPD better.32,33Table 4 Cox Regression analysis to investigate factors predictin
Model without SGRQ, r2Z 0.34 Risk Ratio
Age (Years) 1.04
BODE Index (Points) 1.34
Charlson (Points) 1.09
Model without BODE, r2Z 0.33 Risk Ratio
Age (years) 1.04
SGRQ total (Points) 1.00
Charlson (Points) 1.09
6MWD, (meters) 0.98
BMI (kg/m2) 0.97
FEV1 (% Predicted) 0.99
SGRQ: Saint George’s Respiratory Questionnaire; BODE: Body mass ind
Bronchodilator Forced Expiratory Volume in 1 s 20 min after inhaled br
Index.There were some limitations to this study. First, the
majority of patients were men and perhaps the findings
may not totally apply to women. We believe that gender
related differences in COPD warrant further investigation.
Second, we only evaluated the SGRQ and the results may
not extend to other instruments of HRQoL. However, Hajiro
et al., have shown that all of the questionnaires designed to
evaluate health related quality of life are highly corre-
lated.34 We would expect further studies to validate our
findings.
In summary, this study shows that the BODE index and
the Saint George’s questionnaire are instruments of value in
the evaluation of patients with COPD. They provide
different information. BODE is a slightly better predictor of
mortality than the SGRQ, and therefore a better instrument
to determine severity of COPD. The SGRQ on the other hand
should be considered an outcome in of itself as it may
better reflect the overall interpretation of the compromise
of patients with this disease.g all cause mortality in the cohort.
Confidence Interval (95%) p value
1.02e1.06 <0.001
1.28e1.43 <0.001
1.02e1.99 0.003
Confidence Interval (95%) p value
1.02e1.06 <0.001
0.98e1.03 0.53
1.03e1.19 <0.001
0.98e0.99 <0.001
0.93e0.99 <0.001
0.97e0.99 0.00
ex, Obstruction, Dyspnea, Exercise capacity; Post BD FEV1: Post-
onchodilator; 6MWD: Six-Minute Walking Distance; BMI: Body Mass
BODE index and quality of life 921Acknowledgments
Special acknowledgments to the medical students Jorge
Dreyse and Claudio Pinto, from the Pontificia Universidad
Cato´lica de Chile, for their collaboration.Conflict of interest statement
All authors declare that they have no financial or personal
relationships with other people or organizations that have
influenced the current work.
References
1. World health report. Geneva: World Health Organization;
2000.
2. Celli BR, MacNee W, the ATS/ERS Task Force Committee
Members. Standards for the diagnosis and treatment of
patients with COPD: a summary of the ATS/ERS position paper.
Eur Respir J 2004;23:932e46.
3. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the
diagnosis, management, and prevention of chronic obstructive
pulmonary disease: GOLD executive summary. Am J Respir Crit
Care Med 2007;176:532e55.
4. Wijkstra PJ, Ten Vergert EM, van der Mark Th W, et al. Relation
of lung function, maximal inspiratory pressure, dyspnea and
quality of life with exercise capacity in patients with chronic
obstructive pulmonary disease. Thorax 1994;49:468e72.
5. Engstrom CP, Persson LO, Larsson S, et al. Functional status
and well being in chronic obstructive pulmonary disease with
regard to clinical parameters and smoking: a descriptive and
comparative study. Thorax 1996;51:825e30.
6. Celli BR, Cote CG, Marin JM, et al. The body-mass index,
airflow obstruction, dyspnea and exercise capacity index in
COPD. New Eng J Med 2004;350:1005e12.
7. Martinez FJ, Foster G, Curtis, for the NETT Research Group,
et al. Predictors of mortality in patients with emphysema and
severe airflow obstruction. Am J Respir Crit Care Med 2006;
173:1326e34.
8. Imfeld S, Bloch KE, Weder W, et al. The BODE index after lung
volume reduction correlates with survival in COPD. Chest 2006;
129:835e6.
9. Ong KC, Earnest A, Lu SJ, et al. A multidimensional grading
system (BODE index) as predictor of hospitalization for COPD.
Chest 2005;128:3810e6.
10. Cote CG, Celli BR. Pulmonary rehabilitation and the BODE
index in COPD. Eur Respir J 2005;26:630e6.
11. Fishman A, Martinez F, Naunheim K, et al. A randomized trial
comparing lung-volume-reduction surgery with medical
therapy for severe emphysema. N Engl J Med 2003;348:
2059e73.
12. Ries AL, Kaplan RM, Limberg TM, et al. Effects of pulmonary
rehabilitation on physiologic and psychosocial outcomes in
patients with chronic obstructive pulmonary disease. Ann
Intern Med 1995;122:823e32.
13. Guell R, Casan P, Belda J, et al. Long-term effects of outpa-
tient rehabilitation of COPD: a randomized trial. Chest 2000;
117:976e83.
14. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ,
Wedzicha JA. Effect of exacerbation on quality of life in
patients with chronic obstructive pulmonary disease. Am J
Respir Crit Care Med 1998;157:1418e22.15. Cote CG, Dordelly LJ, Celli BR. Impact of exacerbations on
patient-centered outcomes. Chest 2007;131(3):696e704.
16. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self
complete measure for chronic airflow limitation: the St
George’s Respiratory Questionnaire. Am Rev Respir Dis 1992;
142:1321e7.
17. Fan VS, Curtis JR, Tu SP, et al. from the Ambulatory Care Quality
Improvement Project Investigators. Using quality of life to
predict hospitalization and mortality in patients with obstruc-
tive lung diseases. Chest 2005;122:429e36.
18. Domingo-Salvany A, Lamarca R, Ferrer M, et al. Health-related
quality of life and mortality in male patients with chronic
obstructive pulmonary disease. Am J Respir Crit Care Med
2002;166:680e5.
19. Mahler DA, Wire P, Horstman D, et al. Effectiveness of flutica-
sone propionate and salmeterol combination delivered via the
Diskus device in the treatment of chronic obstructive pulmonary
disease. Am J Respir Crit Care Med 2002;166:1084e91.
20. Medinas M, Mas C, Renom F, Rubi M, Centeno MJ, Gorriz MT.
Health-related quality of life is associated with COPD severity:
a comparison between the GOLD staging and the BODE index.
Chron Respir Dis 2009;6:75e80.
21. Araujo ZT, Holanga G. Does BODE index correlate with quality
of life in patients with COPD? J Bras Pneumol 2010;36:447e52.
22. Standardization of spirometry: 1994 update. American Thoracic
Society. Am J Respir Crit Care Med 1994;152:1107e36.
23. ATS Statement: guidelines for the six-minute walk test. Am J
Respir Crit Care Med 2002;166:111e7.
24. Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The
measurement of dyspnea: contents, inter-observer agreement,
and physiologic correlates of two new clinical indexes. Chest
1984;85:751e8.
25. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of
a combined co morbidity index. J Clin Epidemiol 1994;47:
1245e51.
26. Gerardi DA, Lovett L, Benoit-Connors ML, Reardon JZ,
ZuWallack RL. Variables related to increasedmortality following
outpatient pulmonary rehabilitation. Eur Respir J 1996;9:
431e5.
27. Pinto-Plata VM, Cote C, Cabral H, Taylor J, Celli BR. The 6-min
walk distance: change overtime and value as a predictor of
survival in severe COPD. Eur Respir J 2004;23:28e33.
28. Casanova C, Cote C, de Torres JP, et al. Inspiratory-to-total
lung capacity ratio predicts mortality in patients with chronic
obstructive pulmonary disease. Am J Respir Crit Care Med
2005;171:591e7.
29. Papaioannou AI, Loukides S, Gourgoulianis KI, Kostikas K.
Global assessment of the COPD patient: time to look beyond
FEV1? Respir Med 2009;103:650e60.
30. Bursas V, Hodder R, Miravitlles M, Korducki L, Towse L,
Kesten S. Health outcomes following treatment for six months
with once daily tiotropium compared with twice daily salme-
terol in patients with COPD. Thorax 2003;58:399e404.
31. Oga T, Nishimura K, Tsukino M, et al. Health status measured
with the CRQ does not predict mortality in COPD. Eur Respir J
2002 Nov;20(5):1147e51.
32. Spruit MA, Watkins M, Edwards LD, et al. Determinants of poor
6-min walking distance in patients with COPD: the ECLIPSE
cohort. Respir Med 2010;104:849e57.
33. Balcells E, Anto´ JM, Gea J, et al. Characteristics of patients
admitted for the first time for COPD exacerbation. Respir Med
2009;103:1293e302.
34. Hajiro T, Nishimura K, Tsukino M, et al. A comparison of the
level of dyspnea vs disease severity in indicating the health-
related quality of life of patients with COPD. Chest 1999;116:
1632e7.
